PMC:7335697 / 19144-19385 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T150","span":{"begin":170,"end":178},"obj":"Disease"},{"id":"T151","span":{"begin":218,"end":239},"obj":"Disease"}],"attributes":[{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0005062"},{"id":"A151","pred":"mondo_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/MONDO_0013730"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T195","span":{"begin":163,"end":169},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T196","span":{"begin":216,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T91","span":{"begin":34,"end":45},"obj":"Chemical"},{"id":"T92","span":{"begin":149,"end":158},"obj":"Chemical"},{"id":"T93","span":{"begin":200,"end":211},"obj":"Chemical"}],"attributes":[{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_64357"},{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_66919"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"489","span":{"begin":9,"end":16},"obj":"Species"},{"id":"490","span":{"begin":62,"end":70},"obj":"Species"},{"id":"496","span":{"begin":34,"end":45},"obj":"Chemical"},{"id":"497","span":{"begin":149,"end":158},"obj":"Chemical"},{"id":"498","span":{"begin":200,"end":211},"obj":"Chemical"},{"id":"501","span":{"begin":170,"end":178},"obj":"Disease"},{"id":"502","span":{"begin":218,"end":239},"obj":"Disease"}],"attributes":[{"id":"A489","pred":"tao:has_database_id","subj":"489","obj":"Tax:9606"},{"id":"A490","pred":"tao:has_database_id","subj":"490","obj":"Tax:9606"},{"id":"A496","pred":"tao:has_database_id","subj":"496","obj":"MESH:C502936"},{"id":"A497","pred":"tao:has_database_id","subj":"497","obj":"MESH:D000069283"},{"id":"A498","pred":"tao:has_database_id","subj":"498","obj":"MESH:C540383"},{"id":"A501","pred":"tao:has_database_id","subj":"501","obj":"MESH:D008223"},{"id":"A502","pred":"tao:has_database_id","subj":"502","obj":"MESH:D006086"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T79","span":{"begin":170,"end":178},"obj":"Phenotype"}],"attributes":[{"id":"A79","pred":"hp_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/HP_0002665"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T237","span":{"begin":0,"end":241},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T162","span":{"begin":34,"end":45},"obj":"DG_35"},{"id":"T70945","span":{"begin":34,"end":45},"obj":"DG_35"}],"text":"Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease)."}